New York, June 20, 2026, 11:05 EDT
- Aditxt closed at $0.0100 on Thursday, jumping 127.27%. Volume topped 5.38 billion shares. U.S. markets were shut Friday for Juneteenth and stayed closed Saturday.
- New SEC Form 4s posted showing HRT Financial LP offloaded 3.13 million Class A shares and DRW Securities moved 126,772 common shares. Both firms disclosed no direct stakes after the sales.
- The coming week may hinge on what traders watch: the big jump in volume, Aditxt’s Ignite Proteomics deal, or worries about Aditxt’s cash, dilution, and its Nasdaq listing risks.
Aditxt, Inc. jumped ahead of the Juneteenth holiday, with shares among the most heavily traded on Thursday’s Nasdaq. The microcap health innovation firm saw big volume, records showed, though new filings revealed some major holders were selling.
No typical Friday follow-through showed up. Nasdaq put June 19, 2026 down as a closed market day for Juneteenth, so traders looking to respond to the rally, insider filings, or the company’s uncertain listing had to wait for regular trading to pick up again on Monday, June 22.
ADTX jumped 127.27% to close at $0.0100 on June 18, according to Yahoo Finance historical data. Shares traded from $0.0090 to $0.0180 during the session. Still, the stock didn’t get back to its June 12 close of $0.0130. On a closing price basis, that put it down about 23% for the holiday-shortened week.
Stronger risk appetite showed up across U.S. stocks Thursday. The S&P 500 added 1.1% and the Nasdaq Composite was up 1.9%. The Russell 2000, tracking small caps, advanced 2.1%, the Associated Press reported. Aditxt’s jump stood out, though the move happened as markets rallied.
The latest SEC filings complicate the straightforward momentum story. HRT Financial LP, shown as a 10% owner, dumped 3,132,480 Aditxt Class A shares at $0.013 on June 16 and reported holding nothing directly after, according to Form 4. DRW Securities, LLC, also listed as a 10% owner, offloaded 126,772 common shares at $0.0079 on June 17 and similarly disclosed zero direct holdings. A Form 4 is the U.S. insider ownership document for executive, director, and large-holder trades.
Ignite Proteomics is still the key focus for Aditxt. On June 9, Aditxt announced that Ignite, its functional proteomics unit, reached a definitive business-combination deal putting Ignite’s value at about $150 million. The plan is to list the new combined company on the New York Stock Exchange. Any listing will depend on approvals and on closing. Functional proteomics looks at what proteins actually do, instead of just looking at genes to guess about disease.
Jeff Busch, who is interim CEO at Aditxt and also runs Ignite, called the planned deal an “important milestone.” He said a standalone public company would offer Ignite “focus, visibility and access to capital.” Ignite is currently focused on breast cancer commercially, with plans to move into other tumor types later on, the company said. BioSpace
Competition is tough and most rivals have more cash. Guardant Health pushes cancer blood tests like Guardant360 Liquid CDx. Natera’s Signatera tracks residual disease using bits of tumor DNA in blood. Tempus AI offers AI-powered precision medicine and genomic testing. Aditxt comes at it from another angle. Ignite, its platform, claims to measure protein and phosphoprotein signaling from tumor tissue, but investors will be watching whether that turns into actual adoption and reimbursement.
Listing trouble remains. Aditxt did a 1-for-27 reverse stock split that took effect May 18, trying to get back above Nasdaq’s $1 minimum bid. The company said in its first-quarter filing that on May 6 Nasdaq staff moved to delist its shares after 30 days below $1. Aditxt has asked for a hearing, which paused the delisting for now.
The risk is clear. Aditxt reported first-quarter sales of $12,159 and posted a net loss of $16.2 million, with $268,852 in cash at the end of March. The company said it hasn’t brought in much revenue, is trying to raise more money, and warned that its current condition raises “substantial doubt” about staying in business. Aditxt said it may not be able to keep operating unless it secures more funding. Securities and Exchange Commission
The focus this week isn’t just whether ADTX gets a green close. Traders are watching for anything on supply, fresh financing numbers, or signs of credibility. Updates could arrive as more big-holder filings, a Nasdaq word, or some news around the Ignite registration process. Without those, ADTX could keep trading like it did last week—small, highly volatile, with shares moving quicker than the news flow.
